Publicacions
Articles científics publicats pels investigadors del Barcelonaβeta Brain Research Center (BBRC), relacionats amb la malaltia d'Alzheimer, la neuroimatge, la memòria i les malalties neurodegeneratives, entre altres camps.
-
Suárez-Calvet M, Salvadó G, de Fortuny BB, Del Campo M.
Blood biomarkers for Alzheimer's disease: from detection to decisions
Lancet -
Molina-Berenguer M, Herrero-Martínez D, Vallbona-Garcia A, Vila-Julià F, Cámara Y, Vales Á, González-Aseguinolaza G, Torres-Torronteras J, Martí R
Systemic delivery of AAV-GFM1 corrects COXPD1 molecular alterations in Gfm1R671C/- mice
EMBO Molecular MedicineAbstractHepatoencephalopathy due to mutations in the nuclear gene GFM1, known as combined oxidative phosphorylation (OXPHOS) deficiency type I (COXPD1), is an autosomal recessive mitochondrial disease caused...
-
Blujdea ER, van Bokhoven P, Martino-Adami PV, Marshe VS, Vromen EM, Hok-A-Hin YS, Boiten WA, Irwin DJ, Chen-Plotkin AS, Lemstra AW, Pijnenburg Y, van der Flier WM, Peters O, Hellmann-Regen J, Priller J, Schneider A, Wiltfang J, Jessen F, Düzel E, Buerger K, Perneczky R, Teipel S, Laske C, Brosseron F; DELCODE Consortium; Del Campo M, Wijdeven R, Visser PJ, Tijms BM, De Jager PL, Ramirez A, Teunissen CE, Vermunt L.
Microglia protein profiles in CSF across Alzheimer's disease clinical stages
Nature AgingAbstractMicroglia are implicated in the progression of Alzheimer's disease (AD) pathology from its earliest stages, suggesting that cerebrospinal fluid (CSF) microglia profiling across clinical AD stages can...
-
Bolsewig K, Bellomo G, Hok-A-Hin YS, Al Idrissi I, Vermunt L, Lleó A, Alcolea D, Sieben A, Engelborghs S, Simonsen AH, Hasselbalch SG, Bech S, Morrema THJ, Hoozemans JJM, Bol JGJM, van Alphen J, Gaetani L, Chiasserini D, Paolini Paoletti F, Parnetti L, Kang S, Lee YG, Jeon S, Lee A, Jeon S, Ye BS, Del Campo Milán M, van der Flier WM, van de Berg WDJ, Lemstra AW, Willemse EAJ, Teunissen CE
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders
Nature MedicineAbstractAccurate diagnosis of dementia with Lewy bodies (DLB) remains challenging, with misdiagnosis potentially leading to harmful treatment decisions. DOPA decarboxylase (DDC) shows promise as a...
-
Hok-A-Hin YS, Bongers B, Bolsewig K, Boonkamp L, Ruiters DN, Lemstra AW, van der Flier WM, Pijnenburg YAL, Del Campo M, Teunissen CE
Development and validation of a novel panel of CSF biomarkers for Alzheimer's disease
Alzheimer's Research & TherapyAbstractBackground: Using proximity extension proteomic arrays (PEA), we previously identified a nine-biomarker CSF protein panel reflecting different biological processes dysregulated in Alzheimer´s disease...
-
Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, Mattsson-Carlgren N, Veverova K, Fowler CJ, Boonkamp L, Houtkamp IM, Koel-Simmerlink M, Verberk IMW, Gaetani L, Toja A, Wojdała AL, Fortea J, Pijnenburg Y, Lemstra A, van der Flier W, Hort J, Otto M, Hansson O, Parnetti L, Masters CL, Lleó A, González-Escalante A, Contador J, Suárez-Calvet M, Fernández-Lebrero A, Puig-Pijoan A, Ortiz-Romero P, Jiménez-Moyano E, Minguillón C, Del Campo M, Teunissen C
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study
Alzheimer's & DementiaAbstractIntroduction: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value...
-
González-Escalante A, Milà-Alomà M, Brum WS, Ashton NJ, Ortiz-Romero P, Shekari M, Campo MD, Anastasi F, Quijano-Rubio C, Kollmorgen G, Minguillón C, Sánchez-Benavides G, Grau-Rivera O, Gispert JD, Zetterberg H, Vilor-Tejedor N, Blennow K, Suárez-Calvet M.
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease
EBioMedicineAbstractBackground: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals...
-
Anastasi F, Fernández-Lebrero A, Ashton NJ, Ortiz-Romero P, Torres-Torronteras J, González-Escalante A, Milà-Alomà M, Contador J, García-Escobar G, Manero-Borràs RM, Navalpotro-Gómez I, Jiménez-Moyano E, Sahajan A, Hao Q, Zhang B, Jeromin A, Le Bastard N, Nadal A, Mousavi T, Kollmorgen G, Carboni M, Grau-Rivera O, Zetterberg H, Del Campo M, Blennow K, Puig-Pijoan A, Suárez-Calvet M.
A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Alzheimer's & DementiaAbstractIntroduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited.
Methods: In this cross...
-
Bolsewig K, Willemse EAJ, Sánchez-Juan P, Rábano A, Martínez M, Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, Mattsson-Carlgren N, Veverova K, Fowler CJ, Boonkamp L, Koel-Simmelink M, Hussainali Z, Ruiters DN, Gaetani L, Toja A, Fortea J, Pijnenburg Y, Lemstra AW, van der Flier WM, Hort J, Otto M, Hansson O, Parnetti L, Masters CL, Lleó A, Teunissen CE, Del Campo Milán M.
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
Nature CommunicationsAbstractDOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic...
-
Del Campo M, Quesada C, Vermunt L, Peeters CFW, Hok-A-Hin YS, Trieu C, Braber AD, Verberk IMW, Visser PJ, Tijms BM, van der Flier WM, Teunissen CE
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals
Molecular NeurodegenerationAbstractThis preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune...
